The validity and reliability of screening measures for depression and anxiety disorders in rheumatoid arthritis.
To test the validity and reliability of screening instruments for depression and anxiety in rheumatoid arthritis (RA). Participants with RA completed the Patient Health Questionnaire (PHQ-2, PHQ-9), Patient Reported Outcomes Measurement Information System Depression Short Form-8a (PROMIS Depression) and Anxiety Short Form-8a (PROMIS Anxiety), Hospital Anxiety and Depression Scale anxiety score (HADS-A) and depression score (HADS-D), Overall Anxiety Severity and Impairment Scale (OASIS), Generalized Anxiety Disorder-2 and 7 item scales (GAD-2, GAD-7) and Kessler-6 scale. Clinical depression and anxiety disorders were confirmed using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Research version (SCID). We reported sensitivity (SENS), specificity (SPEC), positive predictive value (PPV) and negative predictive value (NPV) using SCID diagnoses as the criterion standard. Test-retest reliability was assessed with the intra-class correlation coefficient (ICC). Of 150 participants, 11.3% had SCID-diagnosed depression, 7.3% SCID-diagnosed generalized anxiety disorder and 19.3% any SCID-diagnosed anxiety disorder. For depression, SENS ranged from HADS-D (cut-point 11: 35%) to PHQ-2 (88%) and PHQ-9 (87%). SPEC ranged from PHQ-9 (77%), PHQ-2 (84%) to HADS-D (cut-point 11: 94%). PPV ranged from 30% to 43%. NPV ranged from 92% to 98%. For generalized anxiety disorder, SENS ranged from HADS-A (cut-point 11: 45%) to HADS-A (cut-point 8: 91%). SPEC ranged from 81% to 89% for all measures except the HADS-A (cut-point 8: 63%). ICC estimates ranging from 0.69 to 0.88 confirmed good test-retest reliability. Depression screening instruments had good diagnostic performance; anxiety instruments were more variable. Identified depression and anxiety require clinical confirmation. This article is protected by copyright. All rights reserved.